Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology

Annual Review of Pathology: Mechanisms of Disease

Volumn 11, Issue , 2016, Pages 523-554

  Boyton, Rosemary J ^a,b   Altmann, Daniel M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bacterial infection; Immunity; Lung; Microbiota

Indexed keywords

INTERLEUKIN 17; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

AIRWAY OBSTRUCTION; ARTICLE; ASPERGILLUS FUMIGATUS; ATYPICAL MYCOBACTERIUM; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BRONCHIECTASIS; BRONCHUS MUCUS; COMMON VARIABLE IMMUNODEFICIENCY; COUGHING; ENVIRONMENTAL FACTOR; ETHNICITY; GENETIC SUSCEPTIBILITY; HAEMOPHILUS; HUMAN; HYPERIMMUNOGLOBULIN E SYNDROME; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION SENSITIVITY; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM; COMPLICATION; IMMUNOLOGY; INFLAMMATION; MICROBIOLOGY; PATHOLOGY; RESPIRATORY TRACT INFECTION;

BRONCHIECTASIS; HUMANS; INFLAMMATION; RESPIRATORY TRACT INFECTIONS;

EID: 84971338602     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012615-044344     Document Type: Article

References (199)

1. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis Non-CF Guideline Group. 2010. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65:577
2. Wilson R, Boyton RJ. 2006. Bronchiectasis. In Encyclopedia of Respiratory Medicine,Vol. 1, ed.GJLaurent, SD Shapiro, pp. 259-68. Oxford, UK: Elsevier
3. Boyton RJ, Altmann DM. 2012. Immune regulation in idiopathic bronchiectasis. Ann. N. Y. Acad. Sci. 1272:68-72
4. Boyton RJ. 2009. Regulation of immunity in bronchiectasis. Med. Mycol. 47(Suppl. 1):S175-82
5. Pasteur MC, Helliwell SM, Houghton SJ,Webb SC, Foweraker JE, et al. 2000. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 162:1277-84
6. Läennec RTH. 1819. De l'auscultation médiate ou Traité du Diagnostic des Maladies des Poumon et du Coeur. Paris: Brosson & Chaudé. 1st ed.
7. Hasse CE. 1846. An Anatomical Description of the Diseases of the Organs of Circulation and Respiration. Transl. and ed.WE Swaine. London: Sydenham Soc.
8. Wall C, Hoyle JC. 1933. Observations on dry bronchiectasis. BMJ 1:597
9. Cole PJ. 1986. Inflammation: A two-edged sword-The model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 147:6-15
10. Cole P. 1989. Host-microbe relationships in chronic respiratory infection. Respiration 55(Suppl. 1):5-8
11. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, et al. 2013. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am. J. Respir. Crit. Care Med. 187:1118-26
12. Boyton RJ, Reynolds CJ, Quigley KJ, Altmann DM. 2013. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin. Exp. Immunol. 171:117-23
13. Rogers GB, van derGast CJ, Cuthbertson L, Thomson SK, Bruce KD, et al. 2013. Clinical measures of disease in adult non-CF bronchiectasis correlate with airwaymicrobiota composition. Thorax 68:731-37
14. Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, et al. 2014. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann. Am. Thorac. Soc. 11:496-503
15. Dickson RP, Martinez FJ,Huffnagle GB. 2014. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 384:691-702
16. Hurst JR. 2014. Microbial dysbiosis in bronchiectasis. Lancet Respir. Med. 2:945-47
17. Purcell P, JaryH, Perry A, Perry JD, StewartCJ, et al. 2014. Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiol. 14:130
18. Singleton R,Morris A, Redding G, Poll J, Holck P, et al. 2000. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr. Pulmonol. 29:182-87
19. Twiss J, Metcalfe R, Edwards E, Byrnes C. 2005. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch. Dis. Child. 90:737-40
20. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ, Working Group on Indigenous Paediatric Respiratory Health. 2002. Bronchiectasis in indigenous children in remote Australian communities. Med. J. Aust. 177:200-4
21. Boyton RJ, Smith J,Ward R, JonesM,OzerovitchL, et al. 2006.HLA-Cand killer cell immunoglobulinlike receptor genes in idiopathic bronchiectasis. Am. J. Respir. Crit. Care Med. 173:327-33
22. Wynn-Williams N. 1953. Bronchiectasis: A study centred on Bedford and its environs. BMJ 1:1194-99
23. Ringshausen FC, de Roux A, PletzMW,Hämäläinen N, WelteT, et al. 2013. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: A population-based study of disease burden and trends. PLOS ONE 8:e71109
24. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. 2000. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 142:432-39
25. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, et al. 2010. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 138:944-49
26. Roberts HJ, Hubbard R. 2010. Trends in bronchiectasis mortality in England and Wales. Respir. Med. 104:981-85
27. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, et al. 2009. Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. Eur. Respir. J. 34:843-49
28. Onen ZP,Gulbay BE, Sen E, Yildiz OA, Saryal S, et al. 2007. Analysis of the factors related to mortality in patients with bronchiectasis. Respir. Med. 101:1390-97
29. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. 2014. Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis. Respir. Med. 108:287-96
30. Goeminne PC, Bijnens E, Nemery B, Nawrot TS, Dupont LJ. 2014. Impact of traffic related air pollution indicators on non-cystic fibrosis bronchiectasis mortality: A cohort analysis. Respir. Res. 15:108
31. Kunst H, Wickremasinghe M, Wells A, Wilson R. 2006. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur. Respir. J. 28:352-57
32. Poppelwell L, Chalmers JD. 2014. Defining severity in non-cystic fibrosis bronchiectasis. Expert Rev. Respir. Med. 8:249-62
33. Martínez-García MA, de Gracia J, Vendrell Relat M, Girón RM, Maíz Carro L, et al. 2014. Multidimensional approach to non-cystic fibrosis bronchiectasis: The FACED score. Eur. Respir. J. 43:1357-67
34. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, et al. 2014. The Bronchiectasis Severity Index: an international derivation and validation study. Am. J. Respir. Crit. Care Med. 189:576-85
35. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, et al. 2004. Clinical features of dominant and recessive interferon γreceptor 1 deficiencies. Lancet 364:2113-21
36. JenkinsMR, Rudd-Schmidt JA, Lopez JA, RamsbottomKM, Mannering SI, et al. 2015. FailedCTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J. Exp.Med. 212:307-17
37. Orange JS. 2013. Natural killer cell deficiency. J. Allergy Clin. Immunol. 132:515-25
38. Potter JL, Matthews LW, Spector S, Lemm J. 1967. Studies on pulmonary secretions. II. Osmolality and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am. Rev. Respir. Dis. 96:83-87
39. Gaga M, Bentley AM, HumbertM, Barkans J, O'Brien F, et al. 1998. Increases inCD4+ Tlymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 53:685-91
40. TsangKW,Chan K,HoP, ZhengL,Ooi GC, et al. 2000. Sputum elastase in steady-state bronchiectasis. Chest 117:420-26
41. Watt AP, Brown V, Courtney J, Kelly M, Garske L, et al. 2004. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 59:231-36
42. Chen AC,MartinML, Lourie R, Rogers GB, Burr LD, et al. 2015. Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation. PLOS ONE 10:e0119325
43. Altmann D, Boyton R. 2015. Nomenclature: replace 'pathogens' with 'perceptogens'. Nature 518:35
44. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. 2007. Microbiologic follow-up study in adult bronchiectasis. Respir. Med. 101:1633-38
45. Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, et al. 2002. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 57:15-19
46. Hare KM, Binks MJ, Grimwood K, Chang AB, Leach AJ, et al. 2012. Culture and PCR detection of Haemophilus influenzae and Haemophilus haemolyticus in Australian Indigenous children with bronchiectasis. J. Clin. Microbiol. 50:2444-45
47. McDonnell MJ, Jary HR, Perry A,MacFarlane JG, Hester KL. 2015. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir. Med. 109:716-26
48. Miszkiel KA,Wells AU, Rubens MB, Cole PJ,Hansell DM. 1997. Effects of airway infection by Pseudomonas aeruginosa: A computed tomographic study. Thorax 52:260-64
49. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. 2006. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur. Respir. J. 28:974-79
50. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-TorderaM, Román-Sánchez P, Soriano J. 2007. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132:1565-72
51. de Wit R, Bouvier T. 2006. 'Everything is everywhere, but, the environment selects'; what did Baas Becking and Beijerinck really say? Environ. Microbiol. 8:755-58
52. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, et al. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Investig. 109:317-25
53. ShanM,Gentile M, Yeiser JR,Walland AC, BornsteinVU, et al. 2013. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 342:447-53
54. King PT, Ngui J, Farmer MW, Hutchinson P, Holmes PW, Holdsworth SR. 2008. Cytotoxic T lymphocyte and natural killer cell responses to non-typeable Haemophilus influenzae. Clin. Exp. Immunol. 152:542-51
55. Harrison A, Baker BD, Munson RS Jr. 2015. Overlapping and complementary oxidative stress defense mechanisms in nontypeable Haemophilus influenzae. J. Bacteriol. 197:277-85
56. Naylor EJ, BakstadD, Biffen M, Thong B, Calverley P. 2007. Haemophilus influenzae induces neutrophil necrosis: A role in chronic obstructive pulmonary disease? Am. J. Respir. Cell Mol. Biol. 37:135-43
57. King PT, Hutchinson PE, Johnson PD, Holmes PW, Freezer NJ, Holdsworth SR. 2003. Adaptive immunity to nontypeable Haemophilus influenzae. Am. J. Respir. Crit. Care Med. 167:587-92
58. Pizzutto SJ, Yerkovich ST, Upham JW, Hales BJ, Thomas WR, Chang AB. 2104. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-γin vitro in response to non-typeable Haemophilus influenzae. PLOS ONE 9:e104236
59. Murphy TF. 2015. Vaccines for nontypeable Haemophilus influenzae: The future is now. Clin. Vaccine Immunol. 22:459-66
60. Pizzutto SJ, Yerkovich ST, Upham JW, Hales BJ, Thomas WR, et al. 2015. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. Vaccine 33:321-26
61. QuigleyKJ, Reynolds CJ,Goudet A,Raynsford EJ, Sergeant R, et al. 2015. Chronic infection by mucoid Pseudomonas aeruginosa associated with dysregulation in T-cell immunity to outer membrane porin F. Am. J. Respir. Crit. Care Med. 191:1250-64
62. Jensen PO,Givskov M, Bjarnsholt T, MoserC. 2010. The immune system versus Pseudomonas aeruginosa biofilms. FEMS Immunol. Med. Microbiol. 59:292-305
63. Gellatly SL, Hancock RE. 2013. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog. Dis. 67:159-73
64. Döring G, Pier GB. 2008. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26:1011-24
65. DöringG,Meisner C, SternM, Flagella Vaccine Trial Study Group. 2007. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. PNAS. 104:11020-25
66. Cattoir V, Narasimhan G, Skurnik D, Aschard H, Roux D, et al. 2013. Transcriptional response of mucoid Pseudomonas aeruginosa to human respiratory mucus. mBio 3:e00410-12
67. Balasubramanian D, Mathee K. 2009. Comparative transcriptome analyses of Pseudomonas aeruginosa. Hum. Genom. 3:349-61
68. Kwak HJ, Moon JY, Choi YW, Kim TH, Sohn JW, et al. 2010. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J. Exp. Med. 222:237-42
69. Chu H, Zhao L, Xiao H, Zhang Z, Zhang J, et al. 2014. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: A meta-analysis. Arch. Med. Sci. 10:661-68
70. Jarand J, Levin A,Zhang L, HuittG,Mitchell JD, DaleyCL. 2011. Clinical andmicrobiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin. Infect. Dis. 52:565-71
71. Griffith DE, Aksamit TR. 2012. Bronchiectasis and nontuberculous mycobacterial disease. Clin. Chest Med. 33:283-95
72. Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. 2015. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol. Rev. 264:74-87
73. Young LS. 1993. Mycobacterial diseases and the compromised host. Clin. Infect. Dis. 17 (Suppl. 2):S436-41
74. Murphy TF, Brauer AL, Grant BJ, Sethi S. 2005. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am. J. Respir. Crit. Care Med. 172:195-99
75. Yang M, Johnson A, Murphy TF. 2011. Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Infect. Immun. 79:846-57
76. Brook I. 2011. Anaerobic infections in children. Adv. Exp. Med. Biol. 697:117-52
77. Tunney MM, FieldTR, Moriarty TF, Patrick S, DoeringG, et al. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177:995-1001
78. Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, et al. 2012. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 64:3083-94
79. Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, et al. 2013. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2:e01202
80. PotempaM, Potempa J, Kantyka T, Nguyen KA,Wawrzonek K. 2009. Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PLOS Pathog. 5:e1000316
81. Nguyen LD, Viscogliosi E, Delhaes L. 2015. The lung mycobiome: an emerging field of the human respiratory microbiome. Frontiers Microbiol. 16:89
82. Kosmidis C, Denning DW. 2015. The clinical spectrum of pulmonary aspergillosis. Thorax 70:270-77
83. Moss RB. 2015. Fungi in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin. Respir. Crit. Care Med. 36:207-16
84. Engel S. 1947. The Child's Lung. London: Arnold
85. Whitwell F. 1952. A study of the pathology and pathogenesis of bronchiectasis. Thorax 7:213-39
86. GaoY,GuanW,XuG,Lin Z, Tang Y, et al. 2015. The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: A prospective study. Chest 147:1635-43
87. Kapur N, Mackay IM, Sloots TP, Masters IB, Chang AB. 2014. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch. Dis. Child. 99:749-53
88. Huttenhower C, Kostic AD, Xavier RJ. 2014. Inflammatory bowel disease as a model for translating the microbiome. Immunity 40:843-54
89. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, et al. 2010. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLOS ONE 5:e11044
90. Mansour SC, Pena OM, Hancock RE. 2014. Host defense peptides: front-line immunomodulators. Trends Immunol. 35:443-50
91. Pernet E, Guillemot L, Burgel PR, Martin C, LambeauG, et al. 2014. Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nat. Commun. 5:5105
92. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, et al. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485-98
93. Atarashi K, Tanoue T, OshimaK, Suda W, Nagano Y, et al. 2013.Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500:232-36
94. Larsen JM, Musavian HS, Butt TM, Ingvorsen C, Thysen AH. 2015. Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp., promote Toll-like receptor 2-independent lung inflammation and pathology. Immunology 144:333-42
95. Lozupone C, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, et al. 2013. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am. J. Respir. Crit. Care Med. 187:1110-17
96. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N. 2014. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20:159-66
97. Walker AW, Duncan SH, Louis P, Flint HJ. 2104. Phylogeny, culturing, and metagenomics of the human gut microbiota. Trends Microbiol. 22:267-74
98. Integrative HMP (iHMP) Research Network Consortium. 2014. The Integrative HumanMicrobiome Project: dynamic analysis ofmicrobiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16:276-89
99. Abubucker S, SegataN, Goll J, Schubert AM, Izard J, et al. 2012. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLOS Comput. Biol. 8:e1002358
100. TurnbaughPJ, LeyRE,HamadyM,Fraser-LiggettCM,KnightR, et al. 2007.TheHuman Microbiome Project. Nature 449:804-10
101. HumanMicrobiome Project Consortium. 2012. Structure, function and diversity of the healthy human microbiome. Nature 486:207-14
102. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, et al. 2015. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio 6:e00037
103. Barfod KK, Roggenbuck M, Hansen LH, Schjorring S, Larsen ST, et al. 2013. The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol. 13:303
104. Segal LN, Alekseyenko AV, Clemente JC, Kulkarni R, Wu B, et al. 2013. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 1:19
105. Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, et al. 2012. Microbial co-occurrence relationships in the human microbiome. PLOS Comput. Biol. 8:e1002606
106. Faith JJ, Ahern PP, Ridaura VK, Cheng J, Gordon JI. 2014. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci. Transl. Med. 6:220ra11
107. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, et al. 2012. Targeted restoration of the intestinal microbiotawith a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLOS Pathog. 8:e1002995
108. Cho I, Blaser MJ. 2012. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13:260-70
109. BrownEM, SadaranganiM, Finlay BB. 2013. The role of the immune system in governing host-microbe interactions in the intestine. Nat. Immunol. 14:660-67
110. Morgan XC, Tickle TL, Sokol H, Gevers D, et al. 2012. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13:R79
111. Eaton TE, Lambie N, Wells AU. 1998. Bronchiectasis following colectomy for Crohn's disease. Thorax 53:529-31
112. Butland RJ, Cole P, Citron KM, Turner-Warwick M. 1981. Chronic bronchial suppuration and inflammatory bowel disease. Q. J. Med. 50:63-75
113. Black H, Mendoza M, Murin S. 2007. Thoracic manifestations of inflammatory bowel disease. Chest 131:524-32
114. Mahadeva R, Flower C, Shneerson J. 1998. Bronchiectasis in association with coeliac disease. Thorax 53:527-29
115. Sollid LM. 2000. Molecular basis of celiac disease. Annu. Rev. Immunol. 18:53-81
116. Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM. 2009. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat. Immunol. 10:1096-101
117. Boyton RJ, Reynolds C, Wahid FN, Jones MG, Ozerovitch L, et al. 2006. IFN γ and CXCR-1 gene polymorphisms in idiopathic bronchiectasis. Tissue Antigens 68:325-30
118. Stockley RA. 1998. Commentary: bronchiectasis and inflammatory bowel disease. Thorax 53:526-27
119. Wilczynska MM, Condliffe AM, McKeon DJ. 2013. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir. Care 58:694-701
120. Demoruelle MK,WeismanMH, Simonian PL, Lynch DA, Sachs PB, et al. 2012. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 64:1756-61
121. El Maghraoui A, Dehhaoui M. 2012. Prevalence and characteristics of lung involvement on high resolution computed tomography in patients with ankylosing spondylitis: A systematic review. Pulm. Med. 2012:965956
122. Soto-CardenasMJ, Perez-De-Lis M, Bove A, Navarro C, Brito-Zeron P, et al. 2010. Bronchiectasis in primary Sjögren's syndrome: prevalence and clinical significance. Clin. Exp. Rheumatol. 28:647-53
123. Fenlon HM, Doran M, Sant SM, Breatnach E. 1996. High-resolution chest CT in systemic lupus erythematosus. Am. J. Roentgenol. 166:301-7
124. Andonopoulos AP, Yarmenitis S, Georgiou P, Bounas A, Vlahanastasi C. 2001. Bronchiectasis in systemic sclerosis: A study using high resolution computed tomography. Clin. Exp. Rheumatol. 19:187-90
125. Homma S, Suzuki A, Sato K. 2013. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin. Exp. Nephrol. 17:667-71
126. De Luca F, ValenziseM, Alaggio R, Arrigo T, Crisafulli G, et al. 2008. Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers. Eur. J. Pediatr. 167:1283-88
127. Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, et al. 2015. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518:337-43
128. Hilton AM, Doyle L. 1978. Immunological abnormalities in bronchiectasis with chronic bronchial suppuration. Br. J. Dis. Chest 72:207-16
129. Demoruelle MK, Deane KD,Holers VM. 2014. When and where does inflammation begin in rheumatoid arthritis? Curr. Opin. Rheumatol. 26:64-71
130. Willis VC, Demoruelle MK,Derber LA, Chartier-Logan CJ, ParishMC. 2013. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum. 65:2545-54
131. Puéchal X, Génin E, Bienvenu T, Le Jeunne C, Dusser DJ. 2014. Poor survival in rheumatoid arthritis associated with bronchiectasis: A family-based cohort study. PLOS ONE 9:e110066
132. Aronoff A, Bywaters E, Fearnley G. 1955. Lung lesions in rheumatoid arthritis. BMJ 2:228-32
133. Allain J, Saraux A, Guedes C, Valls I, Devauchelle V. 1997. Prevalence of symptomatic bronchiectasis in patients with rheumatoid arthritis. Rev. Rhum. Engl. Ed. 64:531-37
134. Mori S, Koga Y, Sugimoto M. 2012. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir. Med. 106:1591-99
135. McShane PJ, Naureckas ET, StrekME. 2012. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 142:159-67
136. McShane PJ,Naureckas ET,TinoG, Strek ME. 2013. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 188:647-56
137. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, et al. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58:15-25
138. Despaux J, Toussirot E, Wendling D. 1997. Bronchectasies et polyarthrite rhumatöide. Fréquence et aspects étiopathogéniques. Revue de la littérature [Bronchiectasis and rheumatoid arthritis. Incidence and etiopathogenic aspects. Review of the literature]. Rev. Med. Intern. 18:144-52
139. Perry E, Stenton C, Kelly C, Eggleton P, Hutchinson D, De Soyza A. 2014. RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients. Eur. Respir. J. 44:1082-85
140. Chen AC,MartinML, Lourie R, Rogers GB, Burr LD, et al. 2015. Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation. PLOS ONE 10:e0119325
141. Sherlock JP, Taylor PC, Buckley CD. 2015. The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases. Curr. Opin. Rheumatol. 27:71-75
142. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA. 2010. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62:2662-72
143. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, et al. 2006. Inducible bronchusassociated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J. Clin. Investig. 116:3183-94
144. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, et al. 2011. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12:639-46
145. Eller J, Lapa e Silva JR, Poulter LW, Lode H, Cole PJ. 1994. Cells and cytokines in chronic bronchial infection. Ann. N. Y. Acad. Sci. 725:331-45
146. Mathis D, Benoist C. 2009. Aire. Annu. Rev. Immunol. 27:287-312
147. Chalmers JD, Hill AT. 2013. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol. Immunol. 55:27-34
148. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. 2000. TAP deficiency syndrome. Clin. Exp. Immunol. 121:173-78
149. Paulson ML, Freeman AF, Holland SM. 2008. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. Curr. Opin. Allergy Clin. Immunol. 8:527-33
150. Holland SM. 2010. Chronic granulomatous disease. Clin. Rev. Allergy Immunol. 38:3-10
151. Fuschillo S, De Felice A, Balzano G. 2008. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur. Respir. J. 31:396-406
152. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, et al. 2013. A Th17-and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 187:621-29
153. Way EE, Chen K, Kolls JK. 2013. Dysregulation in lung immunity-The protective and pathologic Th17 response in infection. Eur. J. Immunol. 43:3116-24
154. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, et al. 2011. The Th17 pathway in cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 184:252-58
155. Fogli LK, SundrudMS, Goel S, Bajwa S, Jensen K, et al. 2013. T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J. Immunol. 191:3100-11
156. King PT, Hutchinson P, Holmes PW, Freezer NJ, Bennett-Wood V, et al. 2006. Assessing immune function in adult bronchiectasis. Clin. Exp. Immunol. 144:440-46
157. De Gracia J, Rodrigo MJ, Morell F, Vendrell M, Miravitlles M, et al. 1996. IgG subclass deficiencies associated with bronchiectasis. Am. J. Respir. Crit. Care Med. 153:650-55
158. Hill SL, Mitchell JL, Burnett D, Stockley RA. 1998. IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax 53:463-68
159. Silva JR, Jones JA, Cole PJ, Poulter LW. 1989. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 44:668-73
160. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971-79
161. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, et al. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130(Pt. 4):1089-104
162. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, et al. 2011. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35:986-96
163. Pitzalis C, Jones GW, Bombardieri M, Jones SA. 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14:447-62
164. Boyton RJ, Smith J, Jones M, Reynolds C, Ozerovitch L, et al. 2008. Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clin. Exp. Immunol. 152:95-101
165. Suarez-AlmazorME, Tao S,Moustarah F, Russell AS,Maksymowych W. 1995. HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis: association with susceptibility but not severity in a city wide community based study. J. Rheumatol. 22:2027-33
166. Khakoo SI, Carrington M. 2006. KIR and disease: A model system or system of models? Immunol. Rev. 214:186-201
167. Boyton RJ, Altmann DM. 2007. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 149:1-8
168. McDonnell MJ, Anwar GA, Rutherford RM, De Soyza A, Worthy S, et al. 2014. Lack of association between KIR and HLA-C type and susceptibility to idiopathic bronchiectasis. Respir.Med. 108:1127-33
169. Wesselkamper SC, Eppert BL, Motz GT, Lau GW, Hassett DJ, et al. 2008. NKG2D is critical for NK cell activation in host defense against Pseudomonas aeruginosa respiratory infection. J. Immunol. 181:5481-89
170. Giamarellos-Bourboulis EJ. 2014. Natural killer cells in sepsis: detrimental role for final outcome. Crit. Care Med. 42:1579-80
171. Miyazaki S, Ishikawa F, Shimizu K, Ubagai T, Edelstein PH, Yamaguchi K. 2007. Gr-1high polymorphonuclear leukocytes and NK cells act via IL-15 to clear intracellular Haemophilus influenzae in experimental murine peritonitis and pneumonia. J. Immunol. 179:5407-14
172. Lu CC, WuTS,Hsu YJ, Chang CJ, Lin CS, et al. 2014.NKcells kill mycobacteria directly by releasing perforin and granulysin. J. Leukoc. Biol. 96:1119-29
173. Currie DC, Saverymuttu SH, Peters AM, Needham SG, George P, et al. 1987. Indium-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis. Lancet 329:1335-39
174. Chalmers JD, Aliberti S, Blasi F. 2015. Management of bronchiectasis in adults. Eur. Respir. J. 45:1446-62
175. Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR. 2015. Emerging drugs for bronchiectasis: an update. Expert Opin. Emerg. Drugs 20:277-97
176. Main E, Grillo L, Rand S. 2015. Airway clearance strategies in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin. Respir. Crit. Care Med. 36:251-66
177. TayGT, ReidDW,Bell SC. 2015. Inhaled antibiotics in cystic fibrosis (CF) and non-CF bronchiectasis. Semin. Respir. Crit. Care Med. 36:267-86
178. Chalmers JD, Loebinger M, Aliberti S. 2015. Challenges in the development of new therapies for bronchiectasis. Expert Opin. Pharm. 16:833-50
179. SidhuMK, Mandal P, Hill AT. 2015. Developing drug therapies in bronchiectasis. Expert Opin. Investig. Drugs 24:169-81
180. De Soyza A, Brown JS, Loebinger MR, Bronchiectasis Research & Academic Network. 2013. Research priorities in bronchiectasis. Thorax 68:695-96
181. Bilton D, LoebingerMR, Wilson R. 2014. Non-cystic fibrosis bronchiectasis: an evidence-base for new therapies. Lancet Respir. Med. 2:958-60
182. Hill AT, Welham S, Reid K, Bucknall CE, British Thoracic Society. 2012. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 67:928-30
183. Blasi F, Chalmers JD, Aliberti S. 2014. COPD and bronchiectasis: phenotype, endotype or comorbidity? COPD 11:603-4
184. Hurst JR, Elborn JS, De Soyza A, BRONCH-UK Consortium. 2015. COPD-bronchiectasis overlap syndrome. Eur. Respir. J. 45:310-13
185. Chalmers JD, SmithMP, McHugh BJ,DoheryC,Govan JR, et al. 2012. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 186:657-65
186. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, et al. 2012. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebocontrolled trial. Lancet 380:660-67
187. Serisier DJ, Martin ML,McGuckinMA, Lourie R, Chen AC, et al. 2013. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 309:1260-7
188. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, et al. 2013. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 309:1251-59
189. Albert RK, Connett J, BaileyWC, Casaburi R, Cooper JA Jr, et al. 2011. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365:689-98
190. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. 2014. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir. Med. 2:988-96
191. Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT. 2013. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 68:39-47
192. Hewison M. 2012. An update on vitamin D and human immunity. Clin. Endocrinol. 76:315-25
193. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, et al. 2014. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371:1198-207
194. Mahler DA, Huang S, Tabrizi M, Bell GM. 2004. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study. Chest 126:926-34
195. van den Berg WB, McInnes IB. 2013. Th17 cells and IL-17-A focus on immunopathogenesis and immunotherapeutics. Semin. Arthritis Rheum. 43:158-70
196. Clarke TB. 2014. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via Nod-like receptor ligands. Infect. Immun. 82:4596-606
197. Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, et al. 2013. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342:866-71
198. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, et al. 1997. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 10:1754-60
199. Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, et al. 2010. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J. Pediatr. 157:1001-5